283 related articles for article (PubMed ID: 23413984)
1. The aspirin cardiovascular/gastrointestinal risk calculator--a tool to aid clinicians in practice.
Lanas A; Polo-Tomás M; Casado-Arroyo R
Aliment Pharmacol Ther; 2013 Apr; 37(7):738-48. PubMed ID: 23413984
[TBL] [Abstract][Full Text] [Related]
2. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.
Saini SD; Fendrick AM; Scheiman JM
Aliment Pharmacol Ther; 2011 Jul; 34(2):243-51. PubMed ID: 21615437
[TBL] [Abstract][Full Text] [Related]
4. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
Rostom A; Moayyedi P; Hunt R;
Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
[TBL] [Abstract][Full Text] [Related]
5. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
Tsai YW; Wen YW; Huang WF; Chen PF; Kuo KN; Hsiao FY
J Gastroenterol; 2011 Jan; 46(1):39-45. PubMed ID: 20811753
[TBL] [Abstract][Full Text] [Related]
7. Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United kingdom primary care.
Martín Merino E; Johansson S; Nagy P; García Rodríguez LA
Am J Cardiol; 2013 Oct; 112(8):1075-82. PubMed ID: 23831164
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk factors of gastrointestinal bleeding in patients on low-dose aspirin therapy after percutaneous coronary intervention in Japan.
Nadatani Y; Watanabe T; Tanigawa T; Sogawa M; Yamagami H; Shiba M; Watanabe K; Tominaga K; Fujiwara Y; Yoshiyama M; Arakawa T
Scand J Gastroenterol; 2013 Mar; 48(3):320-5. PubMed ID: 23298342
[TBL] [Abstract][Full Text] [Related]
9. Strategies to reduce the GI risks of antiplatelet therapy.
Scheiman JM
Rev Cardiovasc Med; 2005; 6 Suppl 4():S23-31. PubMed ID: 17710073
[TBL] [Abstract][Full Text] [Related]
10. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.
Sung JJ; Lau JY; Ching JY; Wu JC; Lee YT; Chiu PW; Leung VK; Wong VW; Chan FK
Ann Intern Med; 2010 Jan; 152(1):1-9. PubMed ID: 19949136
[TBL] [Abstract][Full Text] [Related]
11. Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.
Peura DA; Wilcox CM
Postgrad Med; 2014 Jan; 126(1):87-96. PubMed ID: 24393755
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin.
Hsu PI; Tsai TJ
Curr Pharm Des; 2015; 21(35):5049-55. PubMed ID: 26369688
[TBL] [Abstract][Full Text] [Related]
13. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy.
Casado Arroyo R; Polo-Tomas M; Roncalés MP; Scheiman J; Lanas A
Heart; 2012 May; 98(9):718-23. PubMed ID: 22523056
[TBL] [Abstract][Full Text] [Related]
14. Daily low-dose aspirin: beware of GI bleeding.
Johns Hopkins Med Lett Health After 50; 2012 Mar; 24(1):6. PubMed ID: 22493823
[No Abstract] [Full Text] [Related]
15. A case-control study of the association between polymorphisms of the endothelial nitric oxide synthase and glycoprotein IIIa genes and upper gastrointestinal bleeding in users of low-dose aspirin.
Piazuelo E; Fuentes J; García-González MA; Jiménez P; Lanas A
Clin Ther; 2008 Jan; 30(1):121-30. PubMed ID: 18343248
[TBL] [Abstract][Full Text] [Related]
16. [Risk and prevention of gastrointestinal complications due to low-dose aspirin and other antiplatelet agents].
Bretagne JF
Rev Prat; 2008 Sep; 58(13):1434-6, 1439-40. PubMed ID: 18924327
[TBL] [Abstract][Full Text] [Related]
17. Reinitiating aspirin therapy for primary prevention of cardiovascular events in a patient post-aspirin-induced upper gastrointestinal bleed: a case report and review of literature.
Adly G; Plakogiannis R
Ann Pharmacother; 2013 Feb; 47(2):e8. PubMed ID: 23386069
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice.
Lanas A
Expert Opin Drug Saf; 2011 Jan; 10(1):45-54. PubMed ID: 20645883
[TBL] [Abstract][Full Text] [Related]
19. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.
Scheiman JM; Herlitz J; Veldhuyzen van Zanten SJ; Lanas A; Agewall S; Nauclér EC; Svedberg LE; Nagy P
J Cardiovasc Pharmacol; 2013 Mar; 61(3):250-7. PubMed ID: 23188121
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
